prises experts from different

fields. Once the committee is

satisfied with the data, it gives

a green signal to proceed to the

next stage. Each clinical trial

site has an ethics committee.

Have vaccine trials been

dropped in late-stage

clinical trials?



Vistara: Tortoise with hares all around it

But slow and steady may not always win the race

ANJULI BHARGAVA New Delhi, 9 September

n early March 2020, Vistara inducted under the travel bubble. its first B787-9 — the Dreamliner — to L launch its international operations, almost five years after it took to the skies, a much-anticipated moment for the Tata-Singapore Airlines joint venture in India.

But as luck would have it, the aircraft arrived to stand on the ground for several months as the Covid-19 pandemic grounded airlines worldwide. For close to six months, the aircraft lav idle and was joined by a second one in August, in consonance with the induction schedule. It is, however, only at the end of August that Vistara decided to launch its maiden international Delhi-London (Heathrow) flight, three times a week as of now. In terms of timing, the induction couldn't have come at a worse moment.

This is as far as the carrier's international operations go. But even its domestic fleet — grounded like those of other airlines — has been lying virtually idle through the pandemic. "The airline has been slow and stodgy in its management in this time of crisis," says an aviation industry analyst. Many in the sector say that Vistara lacks the light-footedness of the airlines with which it competes. Airlines such as SpiceJet took the lead in pushing revenues through cargo and charter operations during the pandemic, a move followed quickly by the market leader IndiGo. Vistara, by contrast, has only recently started focusing on both these revenue-earning streams.

In an email response the company said that it was taking a deeper dive into cargo and charter operations, increasing its revenue through cargo and doing more charters. "During the lockdown, Vistara operated 34 special cargo flights in a little over a month's time to transport more than 220 tonnes of essential commercial goods, relief material, and medical supplies," a spokesperson said. The airline said that it had pulled its Dreamliner into cargo operations, too. had also done a few international charters - without specifying how many and would now be doing some flights

The airline currently operates around 50 domestic flights a day, compared with close to 125 flights for SpiceJet and 500odd for IndiGo. Ever since flights resumed, many carriers are taking bookings for flights to collect cash but cancelling them at the last minute due to very poor loads. The carriers find themselves in a "chicken and egg" situation. Carriers need to fly more and win back passenger confidence. But loads are very low and don't justify operations, so carriers are for

loads to pick up to add more flights. "Only if they fly more will loads FLYING LOW pick up," argues an official in the Directorate General of Civil Aviation. A bloodbath on their books is unav-Vistara*: ₹1,800 oidable for now, he says. "The danger of

Vistara

*source: industry going the 'Kingfisher way', a mon-

FY20 LOSSES (₹crore)

IndiGo: ₹230

SpiceJet: ₹930

ey guzzler with no hope of returns, is the big worry," says an industry source. The pandemic and the consequent hit on airlines coupled with Vistara's almost tortoise-like approach is pointing towards far higher losses in FY21. According to CAPA India Research, Vistara's losses for FY20 are ₹1.270 crore and will cross ₹1.800 crore in FY21 (being unlisted Vistara does not reveal its financials). But industry sources say CAPA's numbers are conservative. Market estimates suggest the airline has already totted up ₹1,800 crore of losses in FY20, and FY21 is expected to see losses in the region of ₹2,500-3,000 crore, because the first quarter is a writeoff and the post-pandemic recovery of the sector is unclear. Domestic losses, they argue, will be compounded by the international ones for this year.

Many are confounded by the sheer size of the airline's losses in FY20. Almost all the Indian players gained substantially in comment on how Vistara is viewed in The spokesperson added that the airline the first quarter of the year gone by due to India's aviation landscape.

Jet's closure and it is argued that one of the biggest gainer from Jet's closure in some sense should have been Vistara as it was the only one offering a business class product on the main trunk routes, just as Jet did. While IndiGo ended the year (despite a far bigger operation) with a loss of ₹230crore and SpiceJet (53 aircraft) with a loss of almost ₹930 crore, Vistara's loss at ₹1,800 crore with 33 aircraft in operation has taken the industry by surprise. "It's hard to see how, when and where the airline anticipates this changing," says one source. The airline in response defended the losses, arguing that it invested in aircraft and expansion and that oil prices remained high through the year.

But more fundamental questions remain up in the air, such as whether the Indian domestic aviation space can at all support a full-service airline. Many believe - based on the experience with both Jet and Kingfisher — that the Indian market can no longer support a full-service carrier. In a recent interview to this paper, IndiGo

CEO Rono Dutta argued that he didn't think there was any space in India's market today for an airline to charge a bit more for this or that. Vistara sources also acknowledge that its "premium economy" gambit tried in its initial days did not work and now the Indian market's price sensitivity cannot support anv extras.

Industry veteran Shakti Lumba adds that "the very fundamentals on which Vistara was set up have been uprooted by Covid-19". In a post-Covid-19 world, he thinks, the airline's chances of success are slim.

Many believe that the Tata group made a cardinal mistake in 2019 when it failed to buy the struggling Jet Airways and merge it into Vistara. Now some feel that the only way for the Tatas to make good of this investment is to buy Air India and try to pull off a successful merger of two "public sector companies", the latter a telling

DECODED

What happens when a vaccine trial runs into a hurdle at Phase 3

SOHINI DAS Mumbai, 9 September

n Tuesday, British drug major AstraZeneca voluntarily suspended clinical trials in the UK for the vaccine candidate developed by the University of Oxford after an event of suspected adverse side effect came to notice. The Indian arm of the trials, however, is continuing with the process. A lot is riding on what is dubbed as one of the front runners for Covid-19 vaccines. When are vaccine trials paused? And what happens now? Let's find out.


Why was the Covishield trial paused in the UK?

The UK arm of the Covishield trial reported an incident of serious illness that needed hospitalisation, but the cause was unexplained. There is. thus, a possibility that the trial participant may have experienced the sickness due to an adverse reaction following the administration of the vaccine.

What is the general process of clinical trials of a vaccine candidate?

There are quite a few stages of clinical trials to investigate a vaccine candidate. First, it is tested on animals - both called pre-clinical trials. Investigators typically check for immunogenicity (immune res-

ЕC



up by symptoms or biochemismall and large. These are cal parameters in blood); or if one develops any adverse immune reactions.

In the Phase 1 of clinical

is collated and put before

comprises experts from

different fields. Once the

the data, it gives a green

ford-AstraZeneca candidate,

signal to proceed to the

next stage



the ethics committee that committee is satisfied with human body.

trials were done on monkeys. Human trials begin with The third phase, of several Phase 1, which involves giving not uncommon.

ponse) and safety profile of a trials, usually carried out on a is collated and put before the

dozen), researchers check whether the vaccine candidate is safe or not, meaning whether or not it induces any harmful side effects in the The Phase 2 trials, usually of severe dengue in people

carried out on a few hundred participants, are mostly about checking whether the vaccine triggers adequate immune response in the body.

thousand participants, is the most comprehensive and also the most time-consuming. In Phase 3 trials, people with underlying conditions, weaknesses or diseases also participate. They have to be RT-PCR negative for the Sars-CoV-2 infection. In Phase 3. some adverse reactions are

After each phase, the data candidate. In case of the Ox- small group of people (a few ethics committee that com- days or weeks.

Most HIV vaccine trials have not been successful. GSK's MAGE-A3 vaccine candidate was dropped due to lack of efficacy. Late-stage trials of Takeda Pharmaceutical's dengue vaccine failed to protect against one of the four types of the virus. Sanofi's dengue vaccine Dengvaxia. which was approved in late 2015 as the world's first vaccine to treat the condition, ran into controversy after it was introduced in the Philippines. It actually increased the risk

When can the Covishield trials re-start?

the disease previously.

who had not been exposed to

The restart of the vaccine trials will depend on the UK medical regulator, the Medicines and Healthcare Products Regulatory Agency. Once it reviews the situation, analyses the cause of unexplained illness in the participant, and is convinced that the vaccine is safe for administering, the trials can re-start. International media reports claim that it can be a matter of a few

PUBLIC NOTICE BRIGHTCOM GROUP LIMITED Certficate No (NSE&BSE - BCG) ECIN202007110006-N dated (NGCBDGC - DGC) Regd. Office: Floor: 5,Fairfield By Marriott,Raod No: 2, Nanakramguda,Gachibowli, Hyderabad - 500032,India. CIN:L64203TG1999PLC030996, Tel: +91 40 6744 9910, Fax: +91 22 6645 9677, www.brightcomgroup.com, email:ir@brightcomgroup.com 11.07.2020 issued by Directorate General of Hydrocarbons(DGH) has been lost. If found, please Statement of Consolidated Financial Results for the Quarter Ended 30th June, 2020 return to - CGM(A&C), OIL HOUSE, Plot No-19, Sector-16A, Consolidated Noida-201301 Quarter ended Year ended Particular March 31, June 30, June 30, March 31. 2020 2020 2019 2020 Audited Audited Unaudited Unaudite 63,954.84 Revenue from operations 62,825.17 57,498,16 269,231.84 2 Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items) 13.894.13 15,819.30 14.833.79 64,262.67 Net Profit / (Loss) for the period before Tax, (after Exceptional and/or Extraordinary items) 13,894.13 15,819.30 61,714.27 4 Net Profit / (Loss) for the period after Tax, after Exceptional and/or Extraordinary items) 10.137.91 10.764.66 8.315.69 44.010.49 otal Comprehensive Income for the period [Comprising F 10.647.80 (61.314.27) 7.655.96 (17,729.50) **R.P.P INFRA PROJECTS LTD.** tax) and Other Comprehensive Income (after tax) 9,525.03 9.525.03 9,525.03 10,153.03 Equity Share Capita SF No. 454, Raghupathynaiken Palayan Railwav Colony Post, Poondurai Road. RP serves (excluding Revaluation Reserve) as shown in the Audited Balance She 273,121.11 Forde - 638 002. CIN: L452017Z1995PLC00611 Tel +91 424 2284077; Fax : +91 424 2282077 E-mail:secretary@rppipl.com, www.rppipl.com of the previous year Earning per share (before Extra rdinary items) (Face Value of Rs.2/-each 2.00 2.26 1.75 9.24 1) Basic NOTICE 2) Diluted 2.00 2.26 1.75 9.24 Notice is hereby given pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) arning per share (after Extraordinary items) (Face Value of Rs.2/-each) 2.00 2.26 1.75 9.24 1) Basic 2.00 2.26 1.75 9.24 2) Diluted Regulations 2015, we hereby intimate you that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 15th of September 2020 at 5.30 Pursuant to Regulation 47(b) of SEBI LODR Regulations, 2015 following items are given on June 30, March 31, June 30, March 31. Stand-alone basis 2020 2020 2019 2020 P.M. onwards inter-alia, to consider, approve and take on record the Unaudited Turnover 11,610.57 12,419.09 11,458.83 46,658.75

Go ahead and call Warren Buffett a Snowflake

No FOMO here: At a time when Berkshire Hathaway isn't making many other fresh bets, it's buying one of the year's hottest tech IPOs

TAE KIM & TARA LACHAPELLE 9 September

s investors fret over whether high-flying technology stocks have gotten too frothy, the recent volatility isn't scaring away Warren Buffett's Berkshire Hathaway — at least not when it comes to getting in on the ground floor of what may be one of the year's most soughtafter tech IPOs. Yes, you read that correctly.

Snowflake, a fast-growing cloud-software and datawarehousing company, filed an amended offering prospectus on Tuesday that revealed Berkshire will buy roughly \$250 million of Snowflake shares at its IPO price and an additional four million shares from another stockholder. The two transactions add up to a roughly \$600 million overall stake in the company if it goes public at the assumed price of \$80 per share, the midpoint of the \$75 to \$85 current range. Snowflake said it plans to raise more than \$2 billion by selling 28 million shares in the public offering.

Don't let the icy name fool you: Snowflake is poised to be one of the hottest deals the industry has seen in a while. When the upstart first filed to go public in late August, the same week as a half-dozen other technology unicorns, a *Bloomberg* column noted at stood out as the most promising of the bunch. With its leadership position in cloud softopen-ended ware and opportunities, it has the kind longtime business partner, years in indexes that track Bloomberg



"In 54 years, I don't think Berkshire's ever bought a new issue." **BUFFETT IN A CNBC INTERVIEW LAST MAY**

pation in the 2018 offering of

Brazilian digital-payments

that's the only example that

comes to mind.) Moreover,

Buffett's dealmaking doctrine

has always been to stay away

from companies and indus-

tries he doesn't understand.

Most consider that to be

one of Buffett's biggest career

mistakes — largely missing

out on the ascent of technol-

ogy giants such as Apple,

Amazon.com and Microsoft.

Kaissar noted last week,

the gains over the last five

of profile and prospects added. (They were apparently investors like to see in a tech forgetting Berkshire's partici-IPO. Snowflake's revenue increased 121 per cent in its most recent quarter, which was significantly higher than most of its public cloud peers. Further, its best-of-breed offering in the data analytics market, which is in the early stages of moving to the cloud, points

It's why, at least until recentto many more quarters of robust growth ahead. ly, Big Tech was never big As promising as Snowflake at Berkshire.


may be, it's unusual to see Berkshire's involvement because Warren Buffett and IPO are two nouns that aren't normally found in the same sentence. "In 54 years, I don't the time how the company think Berkshire's ever bought a new issue," Buffett said in a CNBC interview last May. "They don't even call us," Charlie Munger, Buffett's

the global market. Berkshire didn't start building its now-\$119 billion Apple position until 2016: it bought into Amazon only last year, and Buffett has called himself an 'idiot" for waiting so long. Neither of those bets were even directed by Buffett himself, instead owing to his investing deputies, Todd Combs and Ted Weschler.

It may be that Team Buffett doesn't want to miss out on the next tech darling, and so it's taking a chance on Snowflake. It is likely whoever pulled the trigger at Berkshire was able look beyond the company's current large losses - including its approximate \$350 million in red ink during its last fiscal year - and see Snowflake's bright future.

Buffett turned 90 last month, and Munger is approaching 97. One thing that was clear at Berkshire's company StoneCo Ltd. But last in-person shareholder meeting, in 2019, was that it needs to do a better job courting the next generation of investors, who may have less fascination with Buffett than with tech pioneers like Elon Musk and Jeff Bezos. And considering Tesla and Amazon's five-year return is more than 500 per cent, compared with Berkshire's 63 per cent, they'd be justified. But look out tech kings: new decade, new Buffett – and one, it appears, who is will-As Bloomberg Opinion's Nir ing to let Berkshire go in new directions. Plus, he needs to those three stocks alone were spend that \$147 billion of responsible for 25 per cent of cash somehow.

company for the Quarter ended 30th June 2020 of F Y 2020-21 and other business, if	48.71	518.01	(2,456.90)	(142.81)
			(_,)	(142.01)
 The above is an extract of the detailed format of the financial results filed with the stoc obligations and Disclosure Requirements) Regulations,2015. The full format of Unaudite websites of BSE Limited (BSE) at www.bseindia.com and National Stock Exchange of India Limited (NSE) at www.nseindia.com. For R.P.P Infra Projects Limited Sd/. Place: Erode Mrs.A.Nithya Date: 09.09.2020 Whole Time Director & CFO Place: 109.09.2020 Whole Time Director & CFO Place: 109.09.2020 Place: I:yderabad 	ed financials mpany's web approved by t d AS) prescrib sary. aration of thes pnomic conditi f information in F	results are ava ssite (www.Brig the Board of Dir wed under section se interim conso ions because o ncluding credit For BRIGHT(M. SURE: Chairman a	Lation 33 of the illation 33 of the illatile on the S yhtcomgroup. ectors of the C on 133 of the co bidated financic f COVID-19, th reports and rel COM GROU SH KUMAR	e SEBI (Listing tock Exchange com) panies Act 2013 al statements. In e Group has, at ated information P LIMITED REDDY g Director



	For HB Portfolio Limited
	Sd/-
	ANIL GOYAL
Place : Gurugram	(Managing Director)
Date : 09/09/2020	DIN: 00001938